resmetirom
![Madrigal Pharmaceuticals, NASH, resmetirom, FDA, priority review, nonalcoholic steatohepatitis](https://pharmtales.com/wp-content/uploads/2023/09/Madrigals-NASH-drug-gets-fast-track-review-from-FDA-no-panel-needed.jpg)
Madrigalās NASH drug gets fast-track review from FDA, no panel needed
Anika Sharma
In the wake of a recent CEO transition, Madrigal Pharmaceuticals has disclosed that its nonalcoholic steatohepatitis (NASH) drug has been ...
In the wake of a recent CEO transition, Madrigal Pharmaceuticals has disclosed that its nonalcoholic steatohepatitis (NASH) drug has been ...